Tekla Net Debt from 2010 to 2026
| HQL Stock | | | USD 16.62 -0.25 -1.48% |
Over extended periods, Net Debt is broadly receding with intermittent volatility. Net Debt is the total debt of Tekla Life Sciences minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.
View All Fundamentals Net Debt | First Reported 1996-09-30 | Previous Quarter -1.00 | Current Value -75.5 K | Quarterly Volatility 6.9 M |
Macro event markers
Dot-com Bubble | Housing Crash | Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
provides competitor comparison context for Tekla Life. This provides competitive positioning context.
Historical Net Debt data for Tekla Life serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Tekla Life Sciences represents a compelling investment opportunity.
Latest Tekla Life's Net Debt Growth Pattern
Below is the plot of the Net Debt of Tekla Life Sciences over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Tekla Life's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
Tekla Net Debt Regression Statistics
| Arithmetic Mean | 241,234 |
| Geometric Mean | 13,918 |
| Coefficient Of Variation | 542.79 |
| Mean Deviation | 688,298 |
| Median | -2,341 |
| Standard Deviation | 1,309,400 |
| Sample Variance | 1.7T |
| Range | 6.1M |
| R-Value | 0.09 |
| Mean Square Error | 1.8T |
| R-Squared | 0.01 |
| Significance | 0.75 |
| Slope | 22,087 |
| Total Sum of Squares | 27.4T |
Tekla Net Debt History
| 2026 | -91.2 K | |
| 2025 | -86.9 K | |
| 2024 | -75.5 K | |
| 2023 | -1.0 | |
| 2022 | -477.0 | |
| 2021 | 10.6 K | |
| 2020 | 1.3 M | |
Other Fundumenentals of Tekla Life Sciences
Tekla Life Net Debt component correlations
Click cells to compare fundamentals
Stock Overview, Methodology & Data Sources
The stock is still going through the normal trading activities.Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange. The profile for Tekla Life integrates fundamentals, price behavior, and sector exposure. Historical patterns suggest somewhat reduced sensitivity to broader economic swings. Tekla Life has a market cap of 484.53 M, P/E of 2.84, ROE of 17.59%.
Methodology
Unless otherwise specified, financial data for Tekla Life Sciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tekla (USA Stocks:HQL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tekla Life Sciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try Portfolio ProphetMore Resources for Tekla Stock Analysis
Reviewing Tekla Life Sciences commonly begins with
financial statements and performance trends. Ratio context helps frame profitability, efficiency, and growth trends for Tekla Life Sciences Stock.
Key reports that frame Tekla Life Sciences Stock are listed below: Tekla Life Correlation provides competitor comparison context for Tekla Life. This provides competitive positioning context.
Analysis related to Tekla Life should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth -0.70 |
Investors evaluate Tekla Life Sciences using market value and book value, each describing different facets of the business. Tekla Life's market capitalization is 484.53 M. A P/B ratio of 0.94 suggests Tekla Life trades near or below book value. Enterprise value stands at 484.46 M. Intrinsic value reflects what Tekla Life's
fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
The concept of value for Tekla Life differs from its quoted price, since each reflects a different lens. For Tekla Life, key inputs include a P/E ratio of 2.84, a P/B ratio of 0.94, a profit margin of 44.16%, and ROE of 17.59%. The quoted price is simply the exchange level where supply meets demand.